Renal cell carcinoma and proteomics

Urologia Internationalis

Volumn 84, Issue 4, 2010, Pages 373-377

  Sandim, Vanessa ^a   Pereira, Denise A ^a   Ornellas, Antonio A ^a   Alves, Gilda ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Mass spectrometry; Proteomics technology; Renal cell carcinoma

Indexed keywords

AGMATINASE; ALDEHYDE REDUCTASE; ALPHA 1 ANTITRYPSIN; ALPHA TROPOMYOSIN; AMINOACYLASE; BIOLOGICAL MARKER; CYTOSOLIC NON SPECIFIC DIPEPTIDASE; ENOYL COENZYME A HYDRATASE; GALECTIN 1; INTERLEUKIN 2; KETOHEXOKINASE; MATRILYSIN; PROTEOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; VIMENTIN; TUMOR MARKER; TUMOR PROTEIN;

BIOINFORMATICS; CANCER SURVIVAL; CAPILLARY ELECTROPHORESIS; DNA SEQUENCE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENOME; HUMAN; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KIDNEY CARCINOMA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN TARGETING; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; ANIMAL; CARCINOMA, RENAL CELL; EARLY DIAGNOSIS; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROCEDURES;

ANIMALS; CARCINOMA, RENAL CELL; EARLY DETECTION OF CANCER; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953206785     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296283     Document Type: Review

References (30)

1. Mancini V: Current insight in renal cell cancer pathology. Urol Oncol 2008; 26: 225-238.
2. Pouessed D, Ouline S: Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. Expert Rev Anticancer Ther 2006; 6: 1761-1767.
3. Banks RE, Craven RA, Harnden P, Madaan S, Joyce A, Selby PJ: Key Clinical issues in renal cancer: a challenges for proteomics. World J Urol 2007; 25: 37-56.
4. Hara T, Honda K, Ono M, Naito K, Hiroashi S, Yamada T: Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. J Urol 2005; 174: 1213-1217.
5. Skates S, Hiopoulos O: Molecular markers for early detection of renal carcinoma: investigative approach. Clin Cancer Res 2004; 10: 6296s-6301s.
6. Alpantaki K, Tsiridis E, Pape HC, Giannoudis PV: Application of clinical proteomics in diagnosis and management of trauma patients. Injury 2007; 38: 263-271.
7. Pandey A, Mann M: Proteomics to study genes and genomes. Nature 2000; 405: 837-846.
8. Wilkins MR, et al: From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY) 1996; 14: 61-65.
9. Celis J, et al: Human 2-D PAGE databases for proteome analysis in health and disease: http://biobase.dk/cgi-bin/celis. FEBS Lett 1996; 398: 129-134.
10. Anderson NG, Anderson NL: Twenty years of two-dimensional electrophoresis: past, present and future. Electrophoresis 1996; 17: 443-453.
11. Janech MG, Raymond JR, Arthur JM: Proteomics in renal research. Am J Physiol Renal Physiol 2007; 292:F501-F512.
12. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan MW, Harris R, Williams KL, Humphery- Smith I: Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium . Electrophoresis 1995; 16: 1090-1094.
13. Tjalsma H, Bolhuis A, Jongbloed JD, Bron S, van Dijl JM: Signal peptide-dependent protein transport in Bacillus subtilis : a genomebased survey of the secretome. Microbiol Mol Biol Rev 2000; 64: 515-547.
14. O'Farrell PH: High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250: 4007-4021.
15. Cutillas P, Burlingame A, Unwin R: Proteomics strategies and their application in studies of renal function. News Physiol Sci 2004; 19: 114-119.
16. Hoorn EJ, Hoffert JD, Knepper MA: The application of DIGE-based proteomics to renal physiology. Nephron Physiol 2006; 104: 61-72.
17. Theodorescu D, Mischak H: Mass spectrometry based proteomics in urine biomarker discovery. World J Urol 2007; 25: 435-443.
18. America AHP, Cordewener JHG: Comparative LC-MS: A landscape of peaks and valleys. Proteomics 2008; 8: 731-749.
19. Barratt J, Topham P: Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007; 177: 361-368.
20. González-Buitrago JM, Ferreira L, Lorenzo I: Urinary proteomics. Clin Chim Acta 2007; 375: 49-56.
21. Thongboonkerd V: Practical points in urinary proteomics. J Proteome Res 2007; 6: 3881-3890.
22. Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF, Mocarelli P: Renal cell carcinoma and normal kidney protein expression. Electrophoresis 1997; 18: 599-604.
23. Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, Kang KR, Hyun JS, Chung KH: Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci 2005; 20: 450-455.
24. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT: Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 2001; 98: 9754-9759.
25. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kültz D, Weiss RH: Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006; 5: 64.
26. Okamura N, Masuda T, Gotoh A, Shirakawa T, Terao S, Kaneko N, Suganuma K, Watanabe M, Matsubara T, Seto R, Matsumoto J, Kawakami M, Yamamori M, Nakamura T, Yagami T, Sakaeda T, Fujisawa M, Nishimura O, Okumura K: Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics 2008; 8: 3194-3203.
27. Sarkissian G, Fergelot P, Lamy PJ, Patard JJ, Culine S, Jouin P, Rioux-Leclercq N, Darbouret B: Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem 2008; 54: 574-581.
28. Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, Belldegrun AS, Pantuck AJ, Libermann TA: Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol 2008; 179: 730-736.
29. Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, Field E, Schatz CR, Estock MA, Ahmed N, Anderson NG, Steiner S: Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004; 4: 1159-1174.
30. Bosso N, Chinello C, Picozzi SCM, Gianazza E, Mainini V, Galbusera C, Raimondo F, Perego R, Casellato S, Rocco F, Ferrero S, Bosari S, Mocarelli P, Kienle MG, Magni F: Human urine biomarkers of renal cell carcinoma evaluated by ClinProt. Proteomics Clin Appl 2008; 2: 1036-1046.